Osimertinib
Medulloblastoma SHH Activated And TP53 Wild-Type
Jonsson Comprehensive Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Medulloblastoma SHH Activated And TP53 Wild-Type cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludeoxyglucose Jonsson Comprehensive Cancer Center | Phase 2 | B |
Nivestim St. Jude Children's Research Hospital | Phase 1 | CC |
Trametinib St. Jude Children's Research Hospital | Phase 1 | CC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
Ribociclib St. Jude Children's Research Hospital | Phase 1 | CC |
Sulanemadlin M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Osimertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →